Anzeige
Mehr »
Samstag, 25.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
363 Leser
Artikel bewerten:
(1)

Nasdaq Stockholm AB: Listing of Biosergen AB, on Nasdaq First North Growth Market (303/21)

Listing of Biosergen AB, on Nasdaq First North Growth Market
Nasdaq Stockholm AB has assessed that Biosergen AB, company registration number
559304-1295 fulfills Nasdaq First North Growth Market's listing requirements. 


Provided that Biosergen AB, applies for admission to trading of its shares and
equity rights on Nasdaq First North Growth Market Sweden, and that the company
can meet the liquidity requirements, first day of trading is expected to be
June 24, 2021. 

As per today's date the company has a total of 23 101 775 shares.



Shares



Short name:               BIOSGN         
----------------------------------------------------------------
Maximum number of shares to be listed: 28 101 775       
----------------------------------------------------------------
ISIN code:               SE0016013460      
----------------------------------------------------------------
Round Lot:               1            
----------------------------------------------------------------
Order book ID:             228458         
----------------------------------------------------------------
Company Registration Number:      559304-1295       
----------------------------------------------------------------
Market segment:             First North STO/8    
----------------------------------------------------------------
Tick Size table:            MiFID II tick size table
----------------------------------------------------------------
MIC code:                SSME          
----------------------------------------------------------------
Trading currency:            SEK           
----------------------------------------------------------------





Equity rights



Short name:                BIOSGN TO1         
----------------------------------------------------------------------
Maximum number of warrants to be listed: 5 000 000          
----------------------------------------------------------------------
Terms:                  1 TO 1 entitles to 1 share 
----------------------------------------------------------------------
Subscription period:           May 30, 2022 - June 10, 2022
----------------------------------------------------------------------
Subscription price:            SEK 20.00          
----------------------------------------------------------------------
Last trading day:             June 8, 2022        
----------------------------------------------------------------------
ISIN code:                SE0016013478        
----------------------------------------------------------------------
Round Lot:                1              
----------------------------------------------------------------------
Order book ID:              228459           
----------------------------------------------------------------------
Market segment:              First North STO/8      
----------------------------------------------------------------------
Tick Size table:             MiFID II tick size table  
----------------------------------------------------------------------
MIC code:                 SSME            
----------------------------------------------------------------------
Trading currency:             SEK             
----------------------------------------------------------------------





Classification





Code Name    
-----------------
20  Health Care
-----------------
2010 Health Care
-----------------





This information is distributed at the request of the Certified Adviser, Erik
Penser Bank AB. For further information, please call Erik Penser Bank AB on
+46846380000.
© 2021 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.